NOVT Novanta Inc.
Novanta Inc., together with its subsidiaries, provides precision medicine, precision manufacturing, medical solutions, robotics and automation solutions, and advanced surgery solutions in the United States and internatio…
Industry Peers
Scientific & Technical Instruments| Headline | Source | Time |
|---|---|---|
Older | ||
![]() 2 Profitable Stocks on Our Watchlist and 1 We Find Risky While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said, “Your margin is my opportunity”. | ||
![]() Is Novanta (NOVT) A Bargain Following Strong Growth And Demand Outlook? Recent commentary on Novanta (NOVT) has focused on its revenue growth profile and projected demand pickup, with solid gross margins drawing new attention to how the stock’s recent returns compare with those fundamentals. Short term trading pressure has been clear, with the share price down 9.2% over the past week and 14.3% over 90 days. Yet Novanta’s year to date share price return of 19.8% and 1 year total shareholder return of 16.1% point to momentum that has cooled rather than... | ||
![]() Is Novanta’s (NOVT) High-Margin Revenue Momentum Redefining Its Competitive Moat? In recent commentary, Novanta (NASDAQ:NOVT) has been highlighted for its multi-year annual revenue growth of 10.7% and a gross margin of 44.4%, reflecting perceived market share gains and strong product positioning. This attention centers on Novanta’s combination of demand acceleration expectations and high-margin products, which analysts view as evidence of superior competitive capabilities. Next, we will examine how this focus on Novanta’s revenue momentum and margins may influence the... | ||
![]() 1 High-Flying Stock Worth Your Attention and 2 We Ignore “You get what you pay for” often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the premium, they typically experience elevated volatility during market downturns when expectations change. | ||
![]() The Zacks Analyst Blog Highlights FANUY, ABBNY, KYCCF, NVDA, ISRG, ILMN, NOVT, BOTZ, ROBO, ROBT and IBOT BOTZ offers diversified exposure to a robotics boom fueled by AI, humanoid robots and industrial automation, as the sector rapidly evolves. | ||
![]() Novanta’s (NOVT) Second Quarter Shows Profits Outrunning Sales On August 5, Novanta Inc. (NASDAQ:NOVT) reported second quarter results showing something rarer than strong revenue growth: profit growth that beat it by a wide margin. Revenue rose 10.3% year over year to $265.8 million, but net income nearly tripled and cash from operations quadrupled. That kind of gap between the top and bottom line […] | ||
![]() 2 Cash-Producing Stocks to Target This Week and 1 We Ignore Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities. | ||
![]() Electronic Components Stocks Q2 Teardown: Novanta (NASDAQ:NOVT) Vs The Rest The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how electronic components stocks fared in Q2, starting with Novanta (NASDAQ:NOVT). | ||
![]() Recent Price Trend in Novanta (NOVT) is Your Friend, Here's Why If you are looking for stocks that are well positioned to maintain their recent uptrend, Novanta (NOVT) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen. | ||
![]() 1 Small-Cap Stock with Promising Prospects and 2 We Brush Off Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors. | ||
![]() 5 Revealing Analyst Questions From Novanta’s Q2 Earnings Call Novanta's second quarter was marked by broad-based organic growth across all business units and a favorable response from the market. Management attributed the strong results to both an acceleration in new product revenue—up more than 50% year-over-year—and operational improvements, including factory consolidations. CEO Matthijs Glastra highlighted that all business units grew organically and pointed to increased customer demand in precision robotics, AI-driven manufacturing, and minimally invas | ||
![]() Novanta (NOVT) Q2 2026 Earnings Call Transcript Organic growth hit a three-year high as AI and robotics demand accelerated. | ||
![]() Are You Looking for a Top Momentum Pick? Why Novanta (NOVT) is a Great Choice Does Novanta (NOVT) have what it takes to be a top stock pick for momentum investors? Let's find out. | ||
NOVT Q2 Deep Dive: Acquisition and Manufacturing Moves Drive Outlook Higher Medicine and manufacturing technology provider Novanta (NASDAQ:NOVT) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 10.3% year on year to $265.8 million. On top of that, next quarter’s revenue guidance ($302 million at the midpoint) was surprisingly good and 14.9% above what analysts were expecting. Its non-GAAP profit of $0.89 per share was 7.2% above analysts’ consensus estimates. | ||
Novanta (NOVT) Lifted Guidance And Closed Riverpoint, Is The Upside Already Priced In? What Novanta’s latest guidance and Q2 results mean for the stock Novanta (NOVT) put fresh numbers on the table on 5 August 2026, pairing new third quarter and full year revenue guidance with second quarter results and the recently closed Riverpoint Medical acquisition. The company now guides third quarter 2026 GAAP revenue to US$300 million to US$304 million, with the range reflecting an expected contribution from Riverpoint Medical and an assumption of steady foreign exchange rates. For full... | ||
Novanta (NOVT) Closes Its Largest Acquisition】【。 Novanta (NasdaqGS:NOVT) has closed its acquisition of RiverPoint Medical, the largest deal in the company's history. The transaction expands Novanta's exposure to medical end markets and is expected to be immediately accretive to revenue growth and margins. Management is accelerating a manufacturing restructuring plan alongside the RiverPoint integration, with potential long-term effects on efficiency and profitability. For investors watching how medical technology companies scale up and... | ||
Novanta Inc (NOVT) (Q2 2026) Earnings Call Highlights: Record Cash Flow and Raised Guidance ... Novanta Inc (NOVT) delivered robust Q2 2026 results with 9% organic growth, record cash flow, and raised full-year guidance following the Riverpoint Medical acquisition. | ||
Novanta Q2 Earnings Call Highlights Novanta (NASDAQ:NOVT) reported second-quarter results marked by 9% organic sales growth, expanding margins and higher operating cash flow, while raising its full-year outlook following the late-July closing of its Riverpoint Medical acquisition. Chair and Chief Executive Officer Matthijs Glastra sa | ||
Increased Bookings Reinforce Novanta’s (NOVT) Broadening Organic Momentum Conestoga Capital Advisors, an asset management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The letter reports a positive market shift towards Small Caps, with the Russell 2000 Index achieving its best first half since 1991 and the Russell 2000 Growth Index up 25.7% in Q2, fueled by AI enthusiasm […] | ||
Novanta (NOVT) Tops Q2 Earnings and Revenue Estimates Novanta (NOVT) delivered earnings and revenue surprises of +7.23% and +1.64%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
Novanta’s (NASDAQ:NOVT) Q2 CY2026 Sales Top Estimates, Guides for Strong Full-Year Sales Medicine and manufacturing technology provider Novanta (NASDAQ:NOVT) announced better-than-expected revenue in Q2 CY2026, with sales up 10.3% year on year to $265.8 million. On top of that, next quarter’s revenue guidance ($302 million at the midpoint) was surprisingly good and 14.9% above what analysts were expecting. Its non-GAAP profit of $0.89 per share was 7.2% above analysts’ consensus estimates. | ||
Universal Display Corp. (OLED) Surpasses Q2 Earnings Estimates Universal Display (OLED) delivered earnings and revenue surprises of +1.92% and -3.93%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
Will Novanta (NOVT) Beat Estimates Again in Its Next Earnings Report? Novanta (NOVT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report. | ||
Novanta (NOVT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release Novanta (NOVT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. | ||
3 Reasons to Avoid NOVT and 1 Stock to Buy Instead Since January 2026, Novanta has been in a holding pattern, posting a small return of 3.3% while floating around $142. | ||
3 Russell 2000 Stocks We Find Risky Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resources than their bigger counterparts, these companies face steeper challenges in scaling their businesses. | ||








